JP2008511628A5 - - Google Patents

Download PDF

Info

Publication number
JP2008511628A5
JP2008511628A5 JP2007530000A JP2007530000A JP2008511628A5 JP 2008511628 A5 JP2008511628 A5 JP 2008511628A5 JP 2007530000 A JP2007530000 A JP 2007530000A JP 2007530000 A JP2007530000 A JP 2007530000A JP 2008511628 A5 JP2008511628 A5 JP 2008511628A5
Authority
JP
Japan
Prior art keywords
composition
preservative
sec
group
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007530000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008511628A (ja
Filing date
Publication date
Priority claimed from US10/928,906 external-priority patent/US20050026924A1/en
Application filed filed Critical
Publication of JP2008511628A publication Critical patent/JP2008511628A/ja
Publication of JP2008511628A5 publication Critical patent/JP2008511628A5/ja
Pending legal-status Critical Current

Links

JP2007530000A 2004-08-27 2005-08-19 α−２−アドレナリンアゴニスト成分を含有する組成物 Pending JP2008511628A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/928,906 US20050026924A1 (en) 2000-07-14 2004-08-27 Compositions containing alpha-2-adrenergic agonist components
PCT/US2005/029707 WO2006026215A1 (en) 2004-08-27 2005-08-17 Compositions containing alpha-2-adrenergic agonist components

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012180411A Division JP2012246304A (ja) 2004-08-27 2012-08-16 α−２−アドレナリンアゴニスト成分を含有する組成物

Publications (2)

Publication Number Publication Date
JP2008511628A JP2008511628A (ja) 2008-04-17
JP2008511628A5 true JP2008511628A5 (enExample) 2008-10-02

Family

ID=35589384

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007530000A Pending JP2008511628A (ja) 2004-08-27 2005-08-19 α−２−アドレナリンアゴニスト成分を含有する組成物
JP2012180411A Pending JP2012246304A (ja) 2004-08-27 2012-08-16 α−２−アドレナリンアゴニスト成分を含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012180411A Pending JP2012246304A (ja) 2004-08-27 2012-08-16 α−２−アドレナリンアゴニスト成分を含有する組成物

Country Status (8)

Country Link
US (1) US20050026924A1 (enExample)
JP (2) JP2008511628A (enExample)
AU (1) AU2005280259A1 (enExample)
BR (1) BRPI0514723B8 (enExample)
CA (1) CA2578784C (enExample)
MX (1) MX2007002383A (enExample)
NZ (1) NZ599669A (enExample)
WO (1) WO2006026215A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110251285A1 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
CN110662543A (zh) * 2017-03-23 2020-01-07 灰色视觉公司 用于治疗眼部疾病的药物和组合物
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP6603785B2 (ja) * 2017-12-08 2019-11-06 千寿製薬株式会社 水溶性高分子を含む水性液剤
JP6730500B2 (ja) * 2018-10-01 2020-07-29 千寿製薬株式会社 水性液剤
JP6797992B1 (ja) * 2019-09-30 2020-12-09 千寿製薬株式会社 水性液剤
JP6901619B2 (ja) * 2019-09-30 2021-07-14 千寿製薬株式会社 水性液剤
GR1010024B (el) 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
JP7002692B2 (ja) * 2020-11-18 2022-02-04 千寿製薬株式会社 水性液剤

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154119B (de) * 1961-11-30 1963-09-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4499077A (en) * 1981-02-03 1985-02-12 Stockel Richard F Anti-microbial compositions and associated methods for preparing the same and for the disinfecting of various objects
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) * 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
IL92351A (en) * 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5352796A (en) * 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JP3527256B2 (ja) * 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
DE69431880T2 (de) * 1993-10-13 2003-09-18 Allergan, Inc. Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
SG44628A1 (en) * 1993-12-17 1997-12-19 Procter & Gamble 6-(2-imidazolinylamino) Quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US5994110A (en) * 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
CN101897704B (zh) * 2000-07-14 2014-10-29 阿勒根公司 含有α-2肾上腺素能激动剂的组合物
JP2004503593A (ja) * 2000-07-14 2004-02-05 アラーガン、インコーポレイテッド 増大した溶解度を持つ治療活性成分を含む組成物
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions

Similar Documents

Publication Publication Date Title
JP2008511628A5 (enExample)
RU2496774C2 (ru) Гетероциклические ингибиторы аспартильной протеазы
JP2009501178A5 (enExample)
JP4255839B2 (ja) コンタクトレンズ用液剤
ATE410502T1 (de) Saure reinigungsmittel für harte oberflächen
CN1878757A (zh) 吡啶酮衍生物及其应用
JP2009530282A5 (enExample)
NZ599669A (en) Compositions containing alpha-2-adrenergic agonist components
WO2009112843A3 (en) Cleaning composition
JPH09506518A (ja) 多価陽イオンキレート剤を用いて、アイケア用品における原生動物の増殖を抑制する方法
KR950016758A (ko) 다이플루프레도네이트를 함유한 안 현탁액
JP2008536886A5 (enExample)
RU2012140493A (ru) Средство для чистки унитаза и способ
JP2008195917A5 (enExample)
RU2013138459A (ru) Жидкая композиция с бромфенаком на водной основе, обладающая консервирующей эффективностью
JP2009527588A5 (enExample)
CN113286798A (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
RU2003123472A (ru) Средство для исследований и лечения в урологии
JP2006000170A (ja) コンタクトレンズ用組成物
RU2007112375A (ru) Раствор для травления титановых сплавов
TNSN07288A1 (en) Composition containing chitosan for sustained drug release
RU2006145782A (ru) Дезинфицирующее средство
JP4993443B2 (ja) 工業用殺菌剤およびそれを用いた殺菌方法
CN102696653A (zh) 一种用于油井硫酸盐还原细菌腐蚀的杀菌剂
RU2023127623A (ru) Суспензия, содержащая производное гетероциклиденацетамида